Evogene urges vote for board slate as dissidents seek wholesale replacement ahead of Sept. 4 meeting
EVGN•Evogene urges support for board nominees
Evogene urged shareholders to back its board nominees at the Sept. 4, 2026 annual meeting amid a dissident campaign.
Dissident shareholders L.I.A. Pure Capital and Invest-Pro pushed for a full board replacement.
Management argued a wholesale reset risks disruption, citing an 18-month overhaul centered on ChemPass AI and partnership-driven drug development.
Evogene highlighted a cut in expected 2026 cash burn to $8.5 million-$9.5 million from about $20.5 million in 2024.
The board refresh plan included adding Yael Margolin and Yoshinori Oikawa; dissidents criticized the company for not detailing an alternative strategy.
